Therapeutic effects of alteplase intravenous thrombolysis on different types of acute cerebral infarction: a controlled randomized analysis

Objective: To test the effects of alteplase (PA) intravenous thrombolysis on different types of acute cerebral infarction (ACI). Methods: One hundred and ten patients with the ACI admitted from April 2018 to April 2019 were selected and randomly assigned to a research group and a reference group equally. The two groups received conventional treatment with a subcutaneous injection of low molecular weight heparin calcium of 5000 IU, and the research group received additional PA intravenous thrombolysis treatment. The therapeutic effects of the two groups were compared. Results: There were no significant differences in terms of general information and National Institutes of Health Stroke Scale (NIHSS) score at TO (P>0.05) between the two groups; the research group garnered better results in the NIHSS scores at T1, T2, T3, and T4 than the reference group (P<0.001); a decrease was found in the Modified Rankin Scale (MRS) after treatment (P<0.001), with lower scores in the research group (P<0.001); the research group obtained a higher total effective rate than the reference group (P<0.05). Remarkably higher Barthel scores of the two groups after treatment were found (P<0.001), with higher scores collected from the research group (P<0.001); patients in the research group enjoyed a lower incidence of bleeding events than the reference group (P<0.05). The levels of Interleukin-1 beta (1L-1 beta), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor alpha (TNF-alpha), superoxide dismutase (SOD), glutathione peroxidase (GSH-px), and malondialdehyde (MDA) were apparently optimized after treatment, with superior results observed in the research group (P<0.05). Conclusion: PA intravenous thrombolysis effectively improves the neurological function of patients with different types of ACI and their quality of life, and reduces bleeding events, which is worthy of promotion.